New Multiple Sclerosis Data Have Been Reported by Researchers at University of Alabama (Health insurance affects the use of disease-modifying therapy…

New Multiple Sclerosis Data Have Been Reported by Researchers at University of Alabama (Health insurance affects the use of disease-modifying therapy in multiple sclerosis)

By a News Reporter-Staff News Editor at Insurance Weekly News -- Current study results on Autoimmune Diseases and Conditions - Multiple Sclerosis have been published. According to news reporting out of Birmingham, Alabama, by VerticalNews editors, research stated, "To evaluate the association between health insurance coverage and disease-modifying therapy (DMT) use for multiple sclerosis (MS). In 2014, we surveyed participants in the North American Research Committee on MS registry regarding health insurance coverage."

Our news journalists obtained a quote from the research from the University of Alabama, "We investigated associations between negative insurance change and (1) the type of insurance, (2) DMT use, (3) use of free/discounted drug programs, and (4) insurance challenges using multivariable logistic regressions. Of 6,662 respondents included in the analysis, 6,562 (98.5%) had health insurance, but 1,472 (22.1%) reported negative insurance change compared with 12 months earlier. Respondents with private insurance were more likely to report negative insurance change than any other insurance. Among respondents not taking DMTs, 6.1% cited insurance/financial concerns as the sole reason. Of respondents taking DMTs, 24.7% partially or completely relied on support from free/discounted drug programs. Of respondents obtaining DMTs through insurance, 3.3% experienced initial insurance denial of DMT use, 2.3% encountered insurance denial of DMT switches, and 1.6% skipped or split doses because of increased copay. For respondents with relapsing-remitting MS, negative insurance change increased their odds of not taking DMTs (odds ratio [OR] 1.50; 1.16-1.93), using free/discounted drug programs for DMTs (OR 1.89; 1.40-2.57), and encountering insurance challenges (OR 2.48; 1.64-3.76). Insurance coverage affects DMT use for persons with MS, and use of free/discounted drug programs is substantial and makes economic analysis that ignores these supplements potentially inaccurate."

According to the news editors, the research concluded: "The rising costs of drugs and changing insurance coverage adversely affect access to treatment for persons with MS."

For more information on this research see: Health insurance affects the use of disease-modifying therapy in multiple sclerosis. Neurology, 2016;87(4):365-374. Neurology can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA. (Lippincott Williams and Wilkins - www.lww.com; Neurology - neurology.org)

Our news journalists report that additional information may be obtained by contacting Alabama Birmingham, Birmingham, AL 35233, United States. Additional authors for this research include R.A. Marrie, A.R. Salter, R. Fox, S.S. Cofield, T. Tyry and G.R. Cutter.

Keywords for this news article include: Birmingham, Alabama, United States, North and Central America, Autoimmune Diseases and Conditions of the Nervous System, CNS Demyelinating Autoimmune Diseases and Conditions, Immune System Diseases, Demyelinating Diseases, Multiple Sclerosis, Health Insurance, Neuroimmunology, Neurology, Therapy, University of Alabama.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC